Notice of Exempt Offering of Securities, item 06b



>



X0708


D


LIVE



0001514946


AXIM BIOTECHNOLOGIES, INC.



45 ROCKEFELLER PLAZA


20TH FLOOR, STE 83


NEW YORK


NY


NEW YORK


10111



(212) 751-0007


NEVADA



AXIM INTERNATIONAL INC.



Corporation



true


2018







George


Anatassov




45 Rockerfeller Plaza


20th Floor, #83


New York


NY


NEW YORK


10111




Executive Officer


Director








Philip


Van Damme




Bijleveldsingel, 93


Nijmegen


P7


NETHERLANDS


6521AP




Executive Officer


Director








LeKhram


Changoer




Bijleveldsingel, 93


Nijmegen


P7


NETHERLANDS


6521AP




Executive Officer


Director








Timothy


R


Scott




45 Rockerfeller Plaza


20th Floor, #83


New York


NY


NEW YORK


10111




Director








Robert


Cunningham




45 Rockerfeller Plaza


20th Floor, #83


New York


NY


NEW YORK


10111




Director








John


W


Huemoeller II




45 Rockerfeller Plaza


20th Floor, #83


New York


NY


NEW YORK


10111




Director








Robert


Malasek




45 Rockerfeller Plaza


20th Floor, #83


New York


NY


NEW YORK


10111




Executive Officer








Blake


N


Schroeder




45 Rockerfeller Plaza


20th Floor, #83


New York


NY


NEW YORK


10111




Director









Biotechnology




$1 - $1,000,000




06b





false




2018-05-16





false




true




false





600000





600000


600000


0






false


1





0




0








0







false



AXIM BIOTECHNOLOGIES, INC.


/s/ George Anastassov


George Anastassov


President


2018-05-17







The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Axim Biotechnologies, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct. 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19) - Oct. 6, 2020
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing - Sept. 30, 2020

Auto Refresh

Feedback